Ovarian Cancer Trial, Recruiting NCT06562647 Sponsor: Cell Origin Biotech (Hangzhou) Co., Ltd. Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06562647
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with advanced ovarian cancer or pancreatic cancer through laboratory testing, whose cancer has not responded to at least one previous treatment, and whose tumour tissue has tested positive for a specific protein called mesothelin.
  • People whose cancer can be measured using a CT or MRI scan, meeting specific size requirements as defined by standard medical guidelines (confirm with trial site).
  • People who have a reasonable level of physical functioning (able to carry out some daily activities) and whose major organs such as the heart, liver, and kidneys are working adequately (confirm with trial site).
  • People whose doctors estimate they have a life expectancy of more than 3 months.
  • Women who could become pregnant must have a negative pregnancy blood test before starting the trial, and must agree to use a highly effective method of contraception for up to 1 year after the last dose of the study treatment.

Who may not be able to join:

  • Women who are currently pregnant or breastfeeding.
  • People who have any active infection that is not under control, including conditions such as active tuberculosis or active hepatitis B virus (HBV) infection.
  • People who have previously received any treatment that specifically targets the mesothelin protein.
  • People who have a history of autoimmune disease (conditions where the immune system attacks the body's own tissues).
  • People who the trial doctor believes will be unable or unwilling to follow the requirements of the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cell Origin Biotech (Hangzhou) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
12 April 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Identification of Maximum Tolerated Dose (MTD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov